Dr. VIGNESH T.P.

Abstract

Purpose: To study the efficacy of oral Eplerenone in the treatment of chronic CSCR (CCSCR) with cystoid macular degeneration(CMD).

Methods: Subjects diagnosed with CCSCR with CMD who were treated with oral eplerenone 25 mg once daily,were selected from our medical records. Best corrected visual acuity ,central macular thickness(CMT) and sub-retinal fluid level(SRF) by SD-OCT,were recorded at baseline and every month follow-up visit, upto 6 months.

Results: There was a statistically significant difference in CMT between baseline and 6th month, follow-up visit. There was a statistically significant difference in SRF levels between baseline and 6 month , follow-up visit . Seven eyes of 9 subjects(77.77%) had complete resolution of SRF at 6 months.

Conclusions: Eplerenone , an aldosterone receptor antagonist, has shown a beneficial effect in our study, in the treatment of CCSCR with CMD. There was significant decrease in CMT as well as SRF levels between baseline and final follow-up.

Full Text